Why it’s important to ask doctors questions about IPF

Why it’s important to ask doctors questions about IPF

Living with a chronic illness takes commitment, patience, and endurance. A lot of energy is required to manage your disease, medication schedules, procedures, and medical equipment. For me, equipment management means keeping my oxygen tanks in working order, as I’ve relied on them to breathe since I was diagnosed…

IPF trial of RNAi therapy starts dosing patients, healthy volunteers

Dosing has begun in a clinical trial evaluating ARO-MMP7, Arrowhead Pharmaceuticals’ investigational RNA interference (RNAi) therapy for idiopathic pulmonary fibrosis (IPF). Expecting to enroll up to 56 healthy volunteers and 21 adults with IPF, the Phase 1/2a trial (NCT05537025) — dubbed AROMMP7-1001 — will evaluate the therapy’s…

RESP Biosensor Will Monitor Respiratory Issues at Home

Strados Labs is teaming up with Boehringer Ingelheim to conduct a pilot study leveraging its RESP Biosensor, a first-of-its-kind device designed to remotely monitor key changes in lung sounds, cough, and other respiratory issues in people with idiopathic pulmonary fibrosis (IPF) and other lung disorders. In Boehringer…

Celebrating Milestones on the Road I Have Traveled

There are certain moments in our lives when a single event becomes indelibly etched into our memory. And the significance of such moments is dictated by each of us. Think about that for a minute. What moments are etched into your memory? Have you dealt with the loss of a…

It’s No. 13 for ‘Broadway Belts for PFF!’ on March 6

The Pulmonary Fibrosis Foundation (PFF) is set to present the 13th edition of “Broadway Belts for PFF!” — an annual glitzy affair that has become the nonprofit’s single-largest fundraiser — on March 6. The gala, which also seeks to heighten awareness of pulmonary fibrosis (PF), will take place…

Phase 3 INOpulse Trial Enrollment Completed; Results Due This Year

The Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis (PF) has enrolled its last patient. Recruitment finished sooner than anticipated, according to INOpulse developer Bellerophon Therapeutics. Top-line results are expected later this year and it’s hoped they will support efforts on…